Evidence with impact

Clinical studies show GammaTile consistently delivers outcomes that matter for patients with operable brain tumors.

A growing body of
peer-reviewed studies shows
consistent results:

Strong local tumor control and low rates of radiation necrosis for patients with operable brain tumors. Explore the evidence that’s shaping the future of brain tumor radiation therapy.1-8

GammaTile® clinical evidence:
Proven local control (LC) and
low rates of radiation necrosis (RN)

Safety and efficacy data review:

Recurrent Meningioma
StudyBrachman 2018
PMID: 30,579,269
Study
Design
Prospective
# Patients 19
# Treated
Tumors
20
Tumor
Type
Meningioma
(Recurrent)
Efficacy
Outcome
Median OS:
26 mos.
89% PFS at 18 mos.
Safety10% RN
10% Pts with Surgical Complications
StudyStudy
Design
# Patients# Treated
Tumors
Tumor TypeEfficacy OutcomeSafety
Newly Dx & Recurrent Brain Mets (BM)
Beckham 2025Retrospective3138BM (Recurrent)87% LC at 12 mos.
94% LC at 12 mos. with GTR
8% Symptomatic RN
2.6% Infection
12.9% LMD
Zeller 2024
PMID: 39429969
Prospective
(Registry)
2830Brain Mets
(Newly Dx)
NR
(Perioperative safety analysis)
Serious AE: 3.6%
Total AE: 21.4%
No AE was definitively related to GammaTile
Dharnipragada 2023
PMID: 37,324,216
Retrospective1010Rapidly Growing
Brain Mets
(Newly Dx & Recurrent)
100% LC at median
follow up of 6.2 mos.
No RN
No Surgical Complications
Kutuk 2023
PMID: 37,722,990
Retrospective1012Brain Mets
(Recurrent)
100% LC at 6, 12, and
18 mos.
8% Symptomatic RN
Imber 2022
PMID: 35,896,906
Prospective2025Brain Mets
(Recurrent)
92% LC at 12 months16% Symptomatic RN
Nakaji 2020
PMID: 33,224,684
Prospective1116Brain Mets
(Newly Dx & Recurrent)
83% LC at 12 mos.
Newly Dx (n=4):
100% LC at 12 mos.
Recurrent (n=12):
80% LC at 12 mos.
12.5% Radiation
Brain Changes
Newly Dx (n=4) = 0%
Recurrent (n=12) = 12.5%
Newly Dx & Recurrent Glioblastoma
Yekula 2024
PMID: 38281303
Prospective77Rapidly Growing GBM
(Newly Dx & Recurrent)
Median OS
Newly Dx (n=3): 11.5 mos.
Recurrent (n=4): 10 mos.
Median PFS (All): 10.6 mos.
No RN
No Surgical Complications
Smith 2022
PMID: 36,322,102
Prospective2828Glioblastoma
(Recurrent)
Median time to LF: 12.1 mos.
Median OS: 25.0 mos.
Median PFS: 11.7 mos.
7% Symptomatic RN
Gessler 2022
PMID: 35,088,050
Prospective2222IDH Wild-type
Glioblastoma
(Recurrent)
86% LC at 6 mos.
81% LC at 12 mos.
Median OS: 24.4 mos.
Median PFS: 8.2 mos.
No RN
9% Pts with Surgical Complications
Recurrent Meningioma
Brachman 2018
PMID: 30,579,269
Prospective1920Meningioma
(Recurrent)
Median OS: 26 mos.
89% PFS at 18 mos.
10% RN
10% Pts with Surgical Complications

Proven local control:Proven
local control:
100% LC with 12 previously irradiated
brain mets | clinical and dosimetric evidence

Clinical evidence: 100% LC at 6, 12 and 18 months |
n = 12 tumors1

Kutuk T, et al. Brachytherapy 2023.

Dosimetric evidence: retrospective dosimetric
review of radiation treatment options:
recurrent brain mets | n = 12 tumors9

Kutuk T, et al. Brachytherapy 2024.

Axial illustration demonstrating the differences in biologically effective dose (BED) distribution amongst the radiation modalities

BED10Gy90% Median

Key Insights

  • GammaTile delivers statistically significant higher biologically effective dose (BED) at the resection cavity (RC) than other modalities (CyberKnife®, p = 0.04, Gamma Knife®, p = 0.005, Proton Therapy, p = 0.003).
  • GammaTile’s BED was significantly lower 5mm away from the RC as compared to CyberKnife® (p = 0.045) and proton therapy (p = 0.03).
  • Dose metrics associated with RN are significantly lower for GammaTile on pairwise comparisons (all p <0.05).

The GammaTile Commitment Pledge
for recurrent brain tumors

If a GammaTile treatment of a recurrent brain tumor is canceled because intraoperative pathology reveals only necrotic tissue, we will update the invoice to reflect a $0 charge.*